Michelle Hastings: Pioneering RNA Therapeutics for Rare Genetic Diseases
Michelle Hastings stands at the forefront of RNA-based therapeutic innovation, leading groundbreaking research that could transform treatments for some of medicine's most challenging diseases. As the Pfizer Upjohn Endowed Professor of Pharmacology and Director of RNA Therapeutics at the University of Michigan Medical School, she directs an NIH-funded research program focused on uncovering the molecular mechanisms underlying human disease and developing precision treatments to correct them.
The scope of her research program is ambitious and far-reaching. Through the Hastings Lab, she and her team investigate molecular dysfunctions associated with a wide range of genetic and neurodegenerative disorders, including Usher syndrome, Batten disease, cystic fibrosis, spinal muscular atrophy, Parkinson's disease, and Alzheimer's disease. Her work explores RNA-targeted approaches, particularly antisense oligonucleotide (ASO) therapies, to develop precision treatments for these complex conditions. This research integrates cutting-edge molecular biology with translational applications, advancing personalized medicine and expanding the therapeutic potential of RNA technologies in ways that could benefit patients worldwide.
Her academic foundation began with a bachelor's degree in biology from St. Olaf College, followed by a Ph.D. in molecular biology from Marquette University. This rigorous training prepared her for a career that has consistently bridged fundamental science with clinical application, establishing her as both a skilled researcher and translational scientist.
Before joining the University of Michigan Medical School in Ann Arbor, she held tenured faculty and leadership positions at Rosalind Franklin University of Medicine and Science, where she also directed the Center for Genetic Diseases. This earlier leadership role demonstrated her ability to build and guide comprehensive research programs focused on understanding genetic mechanisms and developing therapeutic interventions for rare and complex conditions.
Her influence extends well beyond the academic laboratory. She serves on scientific advisory boards for biotechnology companies, helping guide the development of innovative therapeutics and ensuring that cutting-edge research translates into real-world treatments. This dual role as both researcher and strategic advisor positions her to shape the development of RNA therapeutics from bench to bedside.
Widely published and recognized for her contributions to molecular biology and genetic medicine, she continues to play a pivotal role in shaping the future of RNA therapeutics and rare disease research. Her work represents the kind of translational science that holds promise for patients with conditions that have long resisted treatment, making her a leader to watch as the field of RNA therapeutics continues to evolve and expand its impact.
